Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $151.5 in the prior trading day, Axsome Therapeutics Inc (NASDAQ: AXSM) closed at $149.03, down -1.63%. In other words, the price has decreased by -$1.63 from its previous closing price. On the day, 0.5 million shares were traded. AXSM stock price reached its highest trading level at $151.58 during the session, while it also had its lowest trading level at $148.59.
Ratios:
Our goal is to gain a better understanding of AXSM by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.50 and its Current Ratio is at 1.57. In the meantime, Its Debt-to-Equity ratio is 2.96 whereas as Long-Term Debt/Eq ratio is at 1.97.
Upgrades & Downgrades
In the most recent recommendation for this company, B. Riley Securities on October 01, 2025, initiated with a Buy rating and assigned the stock a target price of $179.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 05 ’25 when Herriot Tabuteau bought 21,775 shares for $135.69 per share.
TABUTEAU HERRIOT sold 91,705 shares of AXSM for $12,136,240 on Nov 03 ’25. The Chief Executive Officer now owns 7,229 shares after completing the transaction at $132.34 per share. On Nov 04 ’25, another insider, TABUTEAU HERRIOT, who serves as the Chief Executive Officer of the company, sold 50,459 shares for $133.79 each. As a result, the insider received 6,750,910 and left with 7,229 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AXSM now has a Market Capitalization of 7512995840 and an Enterprise Value of 7406319616. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.39 while its Price-to-Book (P/B) ratio in mrq is 101.69. Its current Enterprise Value per Revenue stands at 13.196 whereas that against EBITDA is -39.406.
Stock Price History:
The Beta on a monthly basis for AXSM is 0.47, which has changed by 0.5076127 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, AXSM has reached a high of $152.94, while it has fallen to a 52-week low of $75.56. The 50-Day Moving Average of the stock is 12.94%, while the 200-Day Moving Average is calculated to be 27.27%.
Shares Statistics:
The stock has traded on average 529.38K shares per day over the past 3-months and 555570 shares per day over the last 10 days, according to various share statistics. A total of 50.31M shares are outstanding, with a floating share count of 41.38M. Insiders hold about 17.91% of the company’s shares, while institutions hold 73.93% stake in the company. Shares short for AXSM as of 1763078400 were 3393844 with a Short Ratio of 6.41, compared to 1760486400 on 3437283. Therefore, it implies a Short% of Shares Outstanding of 3393844 and a Short% of Float of 8.01.
Earnings Estimates
. The current assessment of Axsome Therapeutics Inc (AXSM) involves the perspectives of 15.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.61, with high estimates of -$0.43 and low estimates of -$0.82.
Analysts are recommending an EPS of between -$3.52 and -$4.28 for the fiscal current year, implying an average EPS of -$3.86. EPS for the following year is $0.26, with 15.0 analysts recommending between $3.03 and -$3.61.
Revenue Estimates
19 analysts predict $187.54M in revenue for. The current quarter. It ranges from a high estimate of $195.2M to a low estimate of $180.94M. As of. The current estimate, Axsome Therapeutics Inc’s year-ago sales were $118.77MFor the next quarter, 19 analysts are estimating revenue of $191.07M. There is a high estimate of $203.7M for the next quarter, whereas the lowest estimate is $177.94M.
A total of 19 analysts have provided revenue estimates for AXSM’s current fiscal year. The highest revenue estimate was $637.7M, while the lowest revenue estimate was $623.43M, resulting in an average revenue estimate of $630.13M. In the same quarter a year ago, actual revenue was $385.69MBased on 20 analysts’ estimates, the company’s revenue will be $978.83M in the next fiscal year. The high estimate is $1.1B and the low estimate is $838.6M.
